Preliminary Observation on the Usefulness of Homoeopathic Medicine Lapis albus 30 Centesimal Potency in Hypertriglyceridaemia: A Retrospective Study

Abstract

Background Hypertriglyceridaemia is a clinical condition where the serum triglyceride level rises above the normal value of 150 mg/dL. It often leads to cardiovascular diseases, and severe hypertriglyceridaemia increases the risk for pancreatitis. All lipid-lowering drugs used in conventional medicines are reported to have adverse side effects. In this scenario, it is prudent to explore a drug that effectively reduces the triglyceride level, without any side effects, in a relatively shorter time. This study aimed to highlight the action of Lapis albus 30 centesimal (30C) in reducing hypertriglyceridaemia.

Materials and Methods A retrospective study of case records of patients who were under medicine Lapis albus 30C for hypertriglyceridaemia, irrespective of age and gender, in outpatient department of National Homoeopathy Research Institute in Mental Health, Kerala, was done. Pre- and post-intervention fasting lipid profile values were analysed and evaluated for the study.

Result There was a clinically important difference in triglyceride level after administration of Lapis albus 30C in 23 cases out of a total of 25 cases.

Conclusion The present study indicates that the medicine Lapis albus 30C can be useful in reducing hypertriglyceridaemia and lends support for exploring the possibility of this medicine in a larger study sample.

Keywords

hypertriglyceridaemia - Lapis albus - calcium hexafluorosilicate

Declaration of Patients' Consent

Consent was obtained from all patients for publication of their treatment results, after the retrospective study.

Author Contributions

The concept was developed and materialised by Dr Vinitha E.R.

Publication History

Article published online:
29 December 2022

• References

• 1 Berglund L, Brunzell JD, Goldberg AC. et al. Endocrine Society. Evaluation and treatment of hyperglyceridimia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97 (09) 2969-2989
• 2 Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176 (08) 1113-1120
• 3 Joshi SR, Anjana RM, Deepa M. et al; ICMR-INDIAB Collaborative Study Group. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One 2014; 9 (05) e96808 DOI: 10.1371/journal.pone.0096808.
• 4 Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl 2012; 7: 31-35 https://link.springer.com/content/pdf/10.1007%2Fs11789-012-0042-x.pdf
• 5 Miller M, Stone NJ, Ballantyne C. et al; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123 (20) 2292-2333
• 6 Rojas-Fernandez C, Hudani Z, Bittner V. Statins and cognitive side effects: what cardiologists need to know. Endocrinol Metab Clin North Am 2016; 45 (01) 101-116
• 7 Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol 2016; 67 (20) 2395-2410
• 8 Grover HS, Luthra S, Maroo S. Are statins really wonder drugs?. J Formos Med Assoc 2014; 113 (12) 892-898
• 9 Partha MP, Mandal B. A Textbook of Homoeopathic Pharmacy. 1st edition. Kolkata: New Central Book Agency (P) Ltd; 2017
• 10 Clarke JH. A Dictionary of Practical Materia Medica. New Delhi: Indian Books and Periodicals; 2006
• 11 Varma PN, Valavan R. Homoeopathic Materia Medica of New Drugs. 1st edition. New Delhi: B Jain Publishers; 2010
• 12 Varma PN. Vaid I. Lapis albus. Encylopedia of Homoeopathic Pharmacopeia. Vol II. New Delhi: B Jain Publishers (P) Ltd; 2002
• 13 Chalia DS. Revisiting the past: review of Central Council for Research in Homoeopathy Quarterly Bulletin vol 17 (1–4) 1995. Indian J Res Homoeopathy. 2016; 10 (01) 83-86
• 14 Govekar JP, Paul VK, Singh K, Oberai P, Roja V. Hyperlipoproteinemia. Clinical Research Studies – Series II. New Delhi: CCRH; 2009: 63-70
• 15 Pay PN. Homoeopathy in hypercholesterolaemia. Br Homeopath J 1980; 69 (03) 161-162
• 16 Nandi M, Raha D. Dose-dependent effect of Baryta carbonicum and Baryta muriaticum in homœopathic trituration on experimentally induced high serum lipid concentration in chickens. Br Homeopath J 1990; 79 (04) 224-227
• 17 Maiti S, Ali KM, Jana K, Chatterjee K, De D, Ghosh D. Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: homeopathic remedy. J Nat Sci Biol Med 2013; 4 (01) 68-73
• 18 Dixit VP, Joshi SC. Role of cholesterinum and clofibrate in correcting increased lipid levels. Indian. J Pharm Sci.. 1986; 48 (03) 60-3 Accessed October 27, 2021 from: https:S//www.ijpsonline.com/abstract/role-of-cholesterinum-and-clofibrate-in-correcting-increased-lipid-levels-2083.html
• 19 Kamath MK. Evidence of effective treatment in homoeopathy for hyperlipidemia. Asian J Homoeopathy 2008; 2 (01) 48-50
• 20 Central Council for Research in Homoeopathy. Protocol for an open-label randomized controlled exploratory trial of homoeopathy on dyslipidemia. Indian J Res Homoeopathy. 2015; 9: 223-229
• 21 International Classification of Disease, Tenth Revision, Clinical Modification. 2019 Oct. Accessed October 27, 2021 from https://www.icd10data.com/ICD10CM/Index/D/Dyslipidemia
• 22 Hahnemann S. Organon of Medicine. (Dudgeon RE, Boericke W, trans). Combined 5th and 6th ed.. New Delhi: B Jain Publishers (P) Ltd; 1921